Scholars Academic Journal of Pharmacy (SAJP) **ISSN 2320-4206 (Online)**
Sch. Acad. J. Pharm., 2014; 3(3): 280-284 **ISSN 2347-9531 (Print)**

(An International Publisher for Academic and Scientific Resources)
www.saspublisher.com

Research Article

Synthesis and Study of Analgesic Activity of Some Novel Ferrocenyl Derivatives of Pyrazole Analogues

S. Sambath Kumar
Research Scholar, Singhania University, Pacheri Bari Jhun Jhunu-333515, Rajasthan, India

***Corresponding author**
S. Sambath Kumar
Email: sambathkumar98@gmail.com

Abstract: Pyrazoles have been studied for over a century as an important class of heterocyclic compounds and continue to attract considerable interest due to the broad range of biological activities they possess. The incorporation of the essential structural features of pyrazoles with a ferrocene moiety could provide new derivatives with unexpected and/or enhanced biological activities since several ferrocene derivatives have already been shown to be active against a number of tumors. For this reason, we investigated the synthesis of ferrocenyl-substituted pyrazoles, such as sI-alkyl/aryl-5-ferrocenylpyrazoles, by employing the reaction between (2-formyl-1-chlorovinyl) ferrocene and hydrazine derivatives. Although this reaction is known, it was not studied in much detail and the low yields of ferrocenyl pyrazoles were obtained. Thus, I had reinvestigated this reaction and improved the yields of pyrazoles by optimizing the reaction conditions. (2-Formyl-1-chlorovinyl) ferrocene was first reacted with the excess amount (3 equivalents) of hydrazine derivative at 25^0C in dioxane under argon for 2 hours, and the resulting mixture was then heated at 100^0C for 6 hours in the same solvent.
Keywords: Ferrocene, pyrazole, 1-alkyl/aryl-5-ferrocenylpyrazoles, 1-alkyl/aryl-3-ferrocenylpytrazoles, hydrazines, Analgesic Activity

INTRODUCTION

The aim of this work is to synthesize some new ferrocenyl-substituted pyrazole derivatives since the incorporation of the essential structural features of pyrazoles with a ferrocene moiety could provide new derivatives with enhanced antitumor and biological activities. Although pyrazoles are among the most thoroughly studied compounds, we were surprised that there has been very limited study of the ferrocenyl-substituted pyrazoles. As part of our general involvement in ferrocene containing potential pharmaceuticals, I investigated the synthesis of ferrocenyl pyrazoles. In particular, although there are numerous methods for the synthesis of pyrazoles, the reaction of (2-formyl-1-chlorovinyl) ferrocene with hydrazines can provide a rapid entry to ferrocenyl pyrazoles. In fact, the reaction of (2-formyl-1-chlorovinyl) ferrocene with hydrazine and phenyl hydrazine was carried out by Terent'ev and his co-workers for the first time but the low yield of products were obtained since these reactions were not investigated in much detail. We have restudied this reaction under a variety of condition and improved the yields of pyrazoles by optimizing reaction conditions. Moreover, we have examined this reaction with 7 hydrazine derivatives.

EXPERIMENTAL SECTION

Synthesis of (2-formyl-1-chlorovinyl) ferrocene

In the first phase of this study, acetyl ferrocene was synthesized from ferrocene. Ferrocene behaves as an aromatic compound and easily undergoes Friedel-Crafts Acylation reaction to form acetyl ferrocene in 80% yield according to a known literature. The reaction was performed by using $AlCl_3$ under argon condition.



Fig. 1 : Synthesis of acetyl ferrocene

Subsequently, (2-formyl-1-chlorovinyl) ferrocene has been prepared from acetyl ferrocene in 93% yield according to known literature. Treatment of acetyl ferrocene with phosphorus oxychloride in dimethyl formamide (DMF) leads to a mixture of (2-formyl-1-chlorovinyl) ferrocene and (1-chlorovinyl) ferrocene with the different product ratio depending on the stoichiometry. However, the formation of (1-chlorovinyl) ferrocene can be effectively suppressed by employing an excess of phosphorus oxychloride. Using DMF as solvent leads to satisfactory results only for small-scale preperations. However, modification of the stoichiometry and experimental conditions led to the above described procedure which is useful for large-scale preperations. Use of conditions employing a comparatively small excess of DMF and phosphorus oxychloride resulting in a heterogeneous reaction mixture, as well as use of solid sodium acetate trihydrate surmount the problems of scale up and enable the removal of organic impurities. The purity and yield of (2-formyl-1-chlorovinyl)ferrocene are substantially improved using the present procedure, and this intermediate is obtained in pure form without need of chromatography [1].

Synthesis of Acetylferrocene

In a dry flask, ferrocene (2 g, 0, 0108 mol) was added and it was dissolved with stirring in dry dichloromethane (15 ml) under argon. To the resultant dark orange/red solution acetyl chloride (1,03 ml, 0, 0118 mol) was added and then flask was immersed in an ice water bath at 0-5 ^{o}C. Anhydrous aluminium chloride (1, 44g, 0, 0108 mol) was added in 10 portions (2min. between each addition). The reaction mixture darkened. It was stirred for 2 h allowing the ice-water warm to room temperature. Solution was recooled and hydrolized with water by slow addition of 4 x 0, 5 ml of cold water. Then, 3 ml of cold water was added more rapidly. The mixture was transferred to a separating funnel and extracted with dichloromethane then organic extracts were combined and washed with 5% sodium hydroxide solution. Red/orange solution was dried over magnesium sulfate for 10 min, then filtered off. Solvent was removed on a rotary evaporator to give a red/orange solid. This solid was purified by flash chromatography on silica gel using hexane as the eluent [2]. The red/orange fraction (R_f = 0.1in 9:1 hexane/ethyl acetate) was collected to give acetyl ferrocene (1, 96 g, 80%).

^{1}H-NMR ($CDCl_3$): δ 4.60 (s, 2H), 4.32 (s,5H), 2.17 (s, 3H); ^{13}C-NMR ($CDCl_3$): δ 79.2 (C), 72.3 (CH), 69.8 (CH), 69.5 (CH), 27.3 (CH_3). The spectral data is in agreement with those reported previously for this compound.

Synthesis of (2-formyl-1-chlorovinyl) ferrocene

To a two necked flask, acetylferrocene (2 g, 8.8 mmol) was placed and addition funnel was connected. N,N-dimethylformamide (DMF) (2.17 ml, 28.2 mmol) was added on it. The system was flushed with argon, cooled to 0^{o}C by means of an ice bath, and the brown reaction mixture was stirred for several minutes. Separately, in a flask joined with argon, DMF (2.17 ml, 28.2 mmol) was added and cooled to 0^{o}C with good stirring phosphorus oxychloride (2.21 ml, 24 mmol) was added. The resulting viscous, red complex was transferred to the dropping funnel and added to the magnetically stirred mixture of acetylferrocene and DMF dropwise over 30 min. Complete addition was assured by washing the addition funnel and walls of the flask with small amount of DMF. The mixture was stirred at 0^{o}C for 2 hr during which time the colour of the reaction mixture changed from dark brown to olive and ultimately to deep blue. Prior to neutralization, 20 ml portion of diethyl ether was added and viscous mixture was stirred vigorously for several minutes. At 0^{o}C, (10.18 g, 74.6mmol) sodium acetate trihydrate was cautiously added to the reaction mixture in one portion followed by addition of 2 ml water with vigorous stirring. The ice bath was removed whereupon the organic layer undergoes a striking colour change from blue to ruby red indicating the formation of the formyl derivative. After 1 hr, an additional 2 ml of diethyl ether was added and stirring was continued for 3 hr at room temperature to ensure complete quenching. The reaction mixture was transferred to a separator funnel with ether and water and mixed thoroughly, and the organic phase was separated. The aqueous phase was extracted several times with ether. The combined organic phases were carefully washed with 20 ml of saturated aqueous sodium bicarbonate solution. The organic phase was dried over magnesium sulfate, filtered and concentrated using a rotary evaporator [3]. The resulting (2-formyl-1-chlorovinyl)ferrocene was obtained as an only product (2.25 g, 93%).

^{1}H-NMR ($CDCl_3$): δ 10.06 (d, 1H, *J*=7.1 Hz), 6.38 (d, 1H, *J*=7.1 Hz), 4.73 (t, 2H, *J*=1.68 Hz), 4.22 (s, 5H). The spectral data is in agreement with those reported previously for this compound.

Reaction of (2-formyl-1-chlorovinyl) ferrocene with phenyl hydrazine hydrochloride salt

General Procedure 1 was followed by using (2-formyl-1-chlorovinyl) ferrocene (300 mg, 1.089 mmol), phenyl hydrazine hydrochloride salt (472.4 mg, 327 mmol). After chromatographic purification, a purple fraction (R_f =0.43 in 9:1 hexane/ethyl acetate) was collected to give 1-phenyl-3-ferrocenylpyrazole (18 mg, 15%) and an orange fraction (R_f =0.21 in 9:1 hexane/ethyl acetate) was collected to give 1-phenyl-5-ferrocenylpyrazole (49 mg, 41%).

^{1}H-NMR ($CDCl_3$): δ 7.84 (d, 1H, *J* =2.4 Hz), 7.71 (d, 2H, *J*=7.8 Hz), 7.44 (t, 2H, *J*=7.8 Hz), 7.25 (t, 1H, *J*=7.8 Hz), 6.48 (d, 1H, *J*=2.4 Hz), 4.76 (s, 2H), 4.29 (s, 2H), 4.07 (s, 5H); ^{13}C-NMR ($CDCl_3$): δ 152.5 (C), 140.3 (C), 129.4 (CH), 127.4 (CH), 126.0 (CH), 119.0 (CH), 105.6 (CH), 78.4 (C), 69.6 (CH), 68.7

(CH), 66.9 (CH); IR (neat): 3742 (s), 3669 (w), 3030 (vw), 2959 (vs), 2865 (s), 1719 (vs), 1681 (b), 1506 (s), 1257 (vs), 1129 (w), 1043 (m), 868 (w), 820 (m); MS (EI): 328 (M^+), 326, 263, 246, 206, 178, 149, 121, 91, 77, 56; HRMS (EI): Calc. For $C_{19}H_{16}{}^{56}FeN_2$: 328.0663. Found: 328.0665.

^{1}H-NMR ($CDCl_3$): δ 7.62 (s, 1H), 7.40 (m, 5H), 6.50 (s, 1H), 4.17 (s, 2H), 4.14 (s, 2H), 4.05 (s, 5H); ^{13}C-NMR ($CDCl_3$): δ 141.5 (c), 140.4 (C), 140.0 (CH), 128.8 (CH), 128.0 (CH), 126.1 (CH), 106.8 (CH), 75.1 (C), 69.9 (CH), 68.8 (CH),68.6 (CH); IR (neat): 3744 (w), 3098 (m), 3048 (s), 1737 (vw), 1665 (s), 1597 (s), 1498 (vs), 1402 (s), 1312 (vw), 1259 (vs), 1145 (s), 923 (s), 822 (vs); MS (EI): 328 (M^+), 326, 263, 235, 207, 170, 153, 121, 77, 56; HRMS (EI): Calc. For $C_{19}H_{16}{}^{56}FeN_2$: 328.0663. Found: 328.0661.

Reaction of (2-formyl-1-chlorovinyl) ferrocene with benzyl hydrazine dihydrochloride salt

General Procedure was followed by using (2-formyl-1-chlorovinyl)ferrocene (100 mg, 0.363 mmol), benzyl hydrazine dihydrochloride salt (212.44 mg, 1.089 mmol). After chromatographic purification, the orange colored fraction (R_f =0.17 in 9:1 hexane/ethyl acetate) was collected to give 1-benzyl-5-ferrocenylpyrazole [4] (68 mg, 55%).

^{1}H-NMR ($CDCl_3$): δ 7.44 (s, 1H), 7.23 (t, 2H, *J*=7.28 Hz), 7.15 (t, 1H, *J*=7.28 Hz), 6.96 (d, 2H, *J*=7.28 Hz), 6.35 (s, 1H, 5.42 (s, 2H), 4.29 (s, 2H), 4.17 (s, 2H), 4.00 (s, 5H); ^{13}C-NMR ($CDCl_3$): δ 141.7 (C), 139.1 (C), 137.7 (CH), 128.6 (CH), 127.3 (CH), 126.3 (CH), 106.0 (CH), 74.9 (C), 70.0 (CH), 68.8 (CH), 68.4 (CH), 53.3 (CH_2); IR(neat): 3096 (w), 2954 (s), 2930 (s), 2858 (w), 1721 (vs), 1673 (b), 1405 (s), 1281 (vs), 1130 (s), 1076 (s), 928 (s), 822 (s); MS (EI): 342 (M^+), 277, 252, 223, 185, 157, 121, 91, 65, 56; HRMS (EI): Calc. For $C_{20}H_{18}{}^{56}FeN_2$: 342.0819. Found: 342.0817.

Reaction of (2-formyl-1-chlorovinyl)ferrocene with 2-hydroxy ethyl hydrazine dihydrochloride salt

General Procedure was followed by using (2-formyl-1-chlorovinyl) ferrocene (100 mg, 0.363 mmol), 2-hydroxy ethyl hydrazine dihydrochloride salt (162.25 mg, 1.089 mmol). After chromatographic purification, the bright yellow coloured fraction (R_f = 0.107 in 1:1 hexane/ethyl acetate) was collected to give 1-(2-hydroxy ethyl)-3-ferrocenylpyrazole (3 mg, 3%) and yellow/orange colored fraction (R_f = 0.054 in 1:1 hexane/ethyl acetate) was collected to give 1-(2-hydroxy ethyl)-5-ferrocenylpyrazole (36.7 mg, 34%).

^{1}H-NMR ($CDCl_3$): δ 7.46 (d, 1H, *J*=1.8 Hz), 6.30 (d, 1H, *J*=1.8 Hz), 4.49 (s, 2H), 4.36 (t, 2H, *J*=4.5 Hz), 4.33 (s, 2H), 4.18 (s, 5H), 4.02 (t, 2H, *J*=4.5 Hz); ^{13}C-NMR ($CDCl_3$): δ 141.4 (C), 138.7 (CH), 106.0 (CH), 74.9 (C), 69.6 (CH), 68.9 (CH), 68.8 (CH), 61.8 (CH_2), 51.0 (CH_2); IR (neat): 3049 (w), 2925 (vs), 2863 (s), 1724 (s), 1623 (b), 1458 (w), 1285 (s), 1142 (w), 1071 (w), 1034 (vw), 824 (s); MS (EI): 296 (M^+), 294, 265, 252, 231, 200, 187, 146, 121, 103; HRMS (EI): Calc. For $C_{15}H_{16}{}^{56}FeN_2O$. Found: 296.0610.

^{1}H-NMR ($CDCl_3$): δ 7.31 (s, 1H), 6.22 (s, 1H), 4.76 (s, 2H), 4.35 (s, 2H), 4.21 (t, 2H, J= 4.3 Hz), 4.12 (s, 5H), 3.97 (t, 2H, J= 4.3 Hz); ^{13}C-NMR ($CDCl_3$): δ 151.3 (C), 130.8(CH), 103.0 (CH), 78.3 (C), 69.4 (CH), 68.3 (CH), 66.6 (CH), 62.1 (CH_2), 53.5 (CH_2); IR (neat): 3051 (s), 2926 (s), 2858 (s), 1727 (s), 1461 (vw), 1376 (w), 1261 (vs), 1243 (b), 1070 (vw), 821 (vw); MS (EI): 296 (M^+), 294, 278, 264, 231, 213, 199, 173, 148, 121, 103, 81; HRMS (EI): Calc. For $C_{15}H_{16}{}^{56}FeN_2O$: 296.0612. Found: 296.0614.

MATERIAL AND METHODS

Chemicals Required

Carboxy Methyl Cellulose (Ranbaxy Fine Chemical LTD., New Delhi)

Ibuprofen (Ibugesic Sus. contains 100mg/5ml, Cipla PVT. LTD. Mumbai)

Solution of Newly Synthesized compound

Instrument Used: Analgesiometer

Experimental Animals

Healthy Wistar albino rats of either sex (150-180 gm) were selected for present study. The animals were grouped and housed in polyacrylic cages, with not more than six animals per cage and maintained under standard laboratory conditions. They were allowed free access to standard dry pellet diet and water ad libitum during the experiment. All experimental procedures were followed in strict accordance with the guideline prescribed by the Committee for the Purpose of Control and Supervision on Experimental on Animals (CPCSEA) and were approved by the Institutional Animal Ethical Committee.

Screening of Analgesic Activity

Analgesic activity by tail flick method

The activity was evaluated by using tail flick method. The Wistar albino rats of either sex were divided into eight group comprising six animals in each group (n=6). Wistar albino rats of either sex with body weight of 150-180 gm were selected for the study. The animals were starved overnight and deprived of water only during the experiment. The negative control group was treated with carboxy methyl cellulose (2% w/v) suspension at a dose of 10 ml/kg body weight. The positive control group was treated with Ibuprofen at a dose of 10mg/kg body weight. The remaining six group received the newly synthesised compound at dosage of 250, 500, 750 mg/kg body weight [5].

The tail flick latency was assayed by the analgesiometer. The strength of the current passing through the nacked nichrome wire was kept constant at 6 ampere. The distance between the heat source and the tail skin was 1.5 cm. The site of application of the radiant heat in the tail skin was maintained at 2.5 cm

measured from the root of the tail. The cut-off reaction time was fixed at 10 sec to avoid tissue damage. The reaction time was recorded using tail flick analgesiometer at basal reaction time, 30, 60, 120 minute interval after the drug administration [6-8].

Experimental design :

All the animals were divided into eight groups and following treatment were carried.

- 2-formyl-1-chlorovinyl ferrocene was given to group I animals.
- Acetyl ferrocene was given to Group II animals
- 2-formyl-1-chlorvinyl ferrocene with phenyl hydrochloride salt solution was given to Group III animals.
- 2-formyl-1-chlorovnyl ferrocene with benzyl hydrazine dihydrochloride salt was given to Group IV animals.
- 2-formyl-1-chlorovinyl ferrocene with 2-hydroxy ethyl hydrazine dihydrochloride salt was given to Group V animals.
- 1-phenyl-3-ferrocenyl pyrazole was given to Group VI animals.
- 1-phenyl-5-ferrocenyl pyrazole was given to Group vii animals.
- 1-(2-hydroxy ethyl)-5-ferrocenyl pyrazole was given to Group VIII animals.

RESULT

The observation were recorded and tabulated in table below:

Among this all the above ferrocenyl derivatives, Acetyl ferrocene was found more effective as analgesic.

- 2-formyl-1-chlorovinyl ferrocene with 2-hydroxy ethyl hydrazine dihydrochloride salt, 1-phenyl-5-ferrocenyl pyrazole; 1-phenyl-3ferrocenyl pyrazole; 1-(2-hydroxy ethyl)-5-ferrocenyl pyrazole) are found significant with respect to the standard and shows good analgesic activity.

Table 1: Evaluation of Analgesic activity of newly synthesised compounds by tail flick method in wistar albino rats

Groups	Dose (mg/kg bodyweight)	Reaction time in sec. (mean ± SEM)			
		Basal reaction time	30 min	1 hr.	2 hr.
Group I	---	3.18±0.40	3.30±0.26	3.66±0.33	3.75±0.32
Group II	10	3.29±0.18	8.35±0.22	8.84±0.70	9.16±0.68
Group III	250	3.30±0.35	4.26±0.29	4.95±0.11	5.12±0.63
Group IV	500	3.22±0.25	6.12±0.20	7.00±0.53	7.41±0.69
Group V	750	3.31±0.11	7.86±0.31	8.20±0.19	8.30±0.58
Group VI	250	3.31±0.27	4.42±0.90	5.18±0.60	5.23±0.34
Group VII	500	3.25±0.38	6.22±0.25	7.25±0.13	7.50±0.70
Group VIII	750	3.33±0.41	7.90±0.28	8.29±0.30	8.38±0.18

*P<0.05, **P<0.01 as compared to control, as per one way analysis of variance (ANOVA) fallowed by Dunnett's multiple comparison test. Value are presented as mean ± SEM, n= 6 animal in each group

ACKNOWLEDGEMENT

The author is grateful to registrar and staff members of Singhania University for providing necessary research laboratory facilities.

REFERENCES

1. Ando K, Minich ML, Li J, Sakya SM, Lundy KM, Cheng H; Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents. European patent EP 1104759, issued October 22, 2003.
2. Hengmaio Pfizer Global Res. and Dev. Cheng, Akiyoshi Pfizer Centr. Res. and Dev. Kawai; Acetylene derivatives as anti-inflammatory/ analygesic agents. European patent EP1104758, issued July 23, 2003.
3. Subas Man Pfizer Global Rch. & Dev. Sakya; Pyrazole derivatives as anti-inflammatory / analgesic agents. European patent EP 1142889, issued October 10, 2001.
4. El-Sawy ER, Ebaid MS, Abo-Salem HM, Al-Sehemi AG, Mandou AH; Synthesis, anti-inflammatory, analgesic and anticonvalsant activities of some new 4, 6-dimethoxy-5-(heterocycles) benzofuran starting from naturally occurring visnagin. Arabian Journal of Chemistry, 2013. Available from http://www.sciencedirect.com/science/ article/pii/S1878535213000129
5. Matsuo M, Tsuji K, Ogino T, Konishi N; Pyrazole derivatives with anti-inflammatory, analgesic and antithrombolic activity. European patent No. EP 0554829, 15 May 2002.
6. Amir M, Kumar S; Synthesis and anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation activities of 3,5-dimethyl pyrazoles, 3-methyl pyrazol-5-ones and 3, 5-disubstituted pyrazolines", Indian Journal of Chemistry section, 2005; 44 B(12): 2532-2537.

7. Ochi T, Jobo-Magari K, Yonezawa A, Matsumori K, Fujii T; Anti-inflammatory and analgesic effects of a novel pyrazole derivative, FR 140423. European Journal of Pharmacology, 1999; 365(2-3) 259-266.
8. Gaston MA, Dias LR, Freitas AC, Miranda AlP , Barrerio EJ; Synthesis and analgesic properties of 5-acyl-aryl hydrazone 1-H pyrazolo [3,4-b] pyridine derivatives. Pharmaceutica Acta Helvetiae, 1996; 71(3):213-219.